P2RX7 and neoplasm: P2X7 pharmacological blockade does not replicate the immunosuppressive effects due to genetic ablation, rather it enhances tumor infiltration by CD4+ T effector cells and diminishes CD39 and CD73 expression, thus reducing immunosuppression in the TME.